EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind

Cedric Hermans, Glenn F Pierce

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.04.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Cedric Hermans und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belg…. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A remarkable step forward in the treatment of hemophilia A has recently been achieved with the development of an Ultra-Long modified factor (F)VIII. Leveraging expertise gained with fusion to immunoglobulin Fc fragments, disconnecting FVIII from endogenous von Willebrand factor (via a D'-D3 fragment), and benefiting from the pharmacokinetic prolongation provided by the addition of hydrophilic polypeptides, efanesoctocog alfa opens a new era in the treatment of hemophilia A. The term Ultra-Long FVIII has been proposed to designate it and differentiate it from extended half-life FVIII. The level of FVIII correction within the normal range for several days provided by this molecule should allow an increasing number of patients to free themselves from the physical and psychological constraints of hemophilia A. Certainly, the burden of weekly intravenous infusions persists but is compensated by a correction of hemostasis whose amplitude and duration remain unmatched by other therapeutic options currently available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansvon Willebrand FactorHalf-LifeCoagulantsImmunoglobulin Fc FragmentsTreatment OutcomeHemostasisInfusions, IntravenousBlood CoagulationAnimalsRecombinant Fusion Proteins

Stichwörter der Autor:innen

extended half-lifefactor VIII concentratehemophiliainnovationnormalization

Substanzen

Factor VIIIF8 protein, humanvon Willebrand FactorCoagulantsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium; World Federation of Hemophilia, Montreal, Quebec, Canada. Electro…
  • World Federation of Hemophilia, Montreal, Quebec, Canada.

Zitieren

APA

Hermans, C., & Pierce, G. F. (2024). Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.04.010

Vancouver

Hermans C, Pierce GF. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.04.010

BibTeX
@article{Hermans2024,
  author = {Hermans, Cedric and Pierce, Glenn F},
  title = {Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.04.010}
}
Kostenlos starten →